NCT00916097View on ClinicalTrials.gov

NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Head and Neck Neoplasms
Interventions
DRUG

DOCETAXEL(XRP6976)

docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle

Trial Locations (3)

Unknown

Sanofi-Aventis Administrative Office, Algiers

Sanofi-Aventis Administrative Office, Casablanca

Sanofi-Aventis Administrative Office, Mégrine

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00916097 - NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT) | Biotech Hunter | Biotech Hunter